Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/Allergan: Breaking Up Is Hard To Do (Unless There’s A New Tax Law)

Executive Summary

The breakup fee for the Pfizer/Allergan merger would be $3.5bn in certain instances, but much lower, just $400m in expense reimbursement, if a party decides to terminate the deal due to an adverse change in law.

You may also be interested in...



A Sneak Peak At Pfizer’s Next-Generation ADC Pipeline

Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.

Stronger Together: Pfizer Highlights Newly Combined Oncology Portfolio

The company showcased its expanded cancer drug pipeline two months after completing the acquisition of Seagen last year.

BIO Chair Ted Love On Drug Pricing And Political Pressure

Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel